AbbVie completes acquisition of Pharmacyclics
26 May 2015 | By Victoria White
AbbVie has completed the acquisition of Pharmacyclics, enhancing AbbVie's scientific and commercial presence in the haematological oncology market...
List view / Grid view
News
Phase III clinical data show Zebinix (eslicarbazepine acetate) to be effective and well tolerated in elderly
26 May 2015 | By Victoria White
Data for anti-epileptic drug eslicarbazepine acetate shows it to be effective and well tolerated in elderly people with partial onset seizures (POS)...
Faron and CMS enter into strategic agreement for the development of Traumakine in China, Hong Kong, Macao and Taiwan
26 May 2015 | By Victoria White
Faron has entered into strategic agreements with CMS and A&B Ltd for the development and commercialisation of Traumakine for the treatment of ARDS...
CHMP adopts positive opinion of Simponi for the treatment of non-radiographic axial spondyloarthritis
26 May 2015 | By Victoria White
CHMP has adopted a positive opinion of Simponi for the treatment of adults with severe active non-radiographic axial spondyloarthritis...
Amgen to terminate participation in co-development and commercialisation of brodalumab
26 May 2015 | By Victoria White
Amgen has announced the termination of its co-development and commercialisation agreement with AstraZeneca for brodalumab...
Amgen receives positive CHMP opinion for use of Repatha for the treatment of high cholesterol
22 May 2015 | By Victoria White
The CHMP has adopted a positive opinion for the marketing authorisation of Amgen’s Repatha for use in certain patients with high cholesterol...
Cristal Therapeutics announces formation of Scientific Advisory Board
22 May 2015 | By Victoria White
Cristal Therapeutics has appointed Rob Liskamp, Twan Lammers, Alberto Gabizon, Maninder Hora and William Zamboni to its new Scientific Advisory Board...
Bristol-Myers Squibb receives positive CHMP Opinion for nivolumab for the treatment of advanced squamous NSCLC in previously-treated patients
22 May 2015 | By Victoria White
The CHMP has adopted a positive opinion recommending that nivolumab be granted approval for the treatment of NSCLC after prior chemotherapy in adults...
FDA accepts for review New Drug Application for Dyanavel XR in ADHD
22 May 2015 | By Victoria White
Tris Pharma has announced that the FDA has accepted for review its New Drug Application for Dyanavel XR, an Extended-Release Oral Suspension...
Afinitor (everolimus) extended progression-free survival in Phase III trial in advanced gastrointestinal or lung neuroendocrine tumours
22 May 2015 | By Victoria White
The Phase III study of everolimus in patients with advanced nonfunctional neuroendocrine tumours (NET) of GI or lung origin met its primary endpoint...
FDA grants Fast Track designation to ReNeuron’s retinitis pigmentosa cell therapy candidate
22 May 2015 | By Victoria White
The US Food and Drug Administration (FDA) has granted Fast Track designation to ReNeuron’s human Retinal Progenitor Cell (hRPC) therapy candidate for retinitis pigmentosa.
Novartis announces two positive US phase III programmes in COPD for QVA149 and NVA237
22 May 2015 | By Victoria White
Novartis has announced positive results from two pivotal Phase III clinical trial programmes for QVA149 and NVA237 in patients with moderate-to-severe COPD...
Nabriva appoints Dr Elyse Seltzer as Chief Medical Officer
22 May 2015 | By Victoria White
Nabriva has announced the appointment of Elyse Seltzer, MD, as Chief Medical Officer. Dr Seltzer assumes the role from Dr William Prince...
DIFICLIR (fidaxomicin) significantly reduces recurrence and all-cause mortality when used first-line in all patients diagnosed with Clostridium difficile infection (CDI)
21 May 2015 | By Victoria White
Data presented from the Clostridium difficile Infection (CDI) Service Evaluation study shows that the adoption pattern of treatment impacts CDI outcomes...
Alnylam receives Orphan Drug Designation for revusiran for the treatment of ATTR amyloidosis
21 May 2015 | By Victoria White
The FDA has granted Orphan Drug Designation to Alnylam’s revusiran for the treatment of transthyretin (TTR)-mediated amyloidosis (ATTR amyloidosis)...
